Drug General Information |
Drug ID |
D01VFR
|
Former ID |
DNC004255
|
Drug Name |
PD-168393
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H13BrN4O
|
Canonical SMILES |
C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br
|
InChI |
1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)
|
InChIKey |
HTUBKQUPEREOGA-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Epidermal growth factor receptor |
Target Info |
Inhibitor |
[2]
|
mRNA of HER2 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
MAPK signaling pathway
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Cytokine-cytokine receptor interaction
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
Endocytosis
|
PI3K-Akt signaling pathway
|
Dorso-ventral axis formation
|
Focal adhesion
|
Adherens junction
|
Gap junction
|
Regulation of actin cytoskeleton
|
GnRH signaling pathway
|
Estrogen signaling pathway
|
Oxytocin signaling pathway
|
Epithelial cell signaling in Helicobacter pylori infection
|
Hepatitis C
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Pancreatic cancer
|
Endometrial cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Bladder cancer
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
Choline metabolism in cancerhsa04012:ErbB signaling pathway
|
NetPath Pathway
|
IL4 Signaling Pathway
|
EGFR1 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
PANTHER Pathway
|
Cadherin signaling pathway
|
EGF receptor signaling pathwayP00012:Cadherin signaling pathway
|
EGF receptor signaling pathway
|
Pathway Interaction Database
|
LPA receptor mediated events
|
Signaling events mediated by PTP1B
|
Arf6 signaling events
|
Signaling events mediated by TCPTP
|
Thromboxane A2 receptor signaling
|
SHP2 signaling
|
Regulation of Telomerase
|
EGF receptor (ErbB1) signaling pathway
|
EGFR-dependent Endothelin signaling events
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Direct p53 effectors
|
ErbB1 downstream signaling
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
E-cadherin signaling in keratinocytes
|
ErbB receptor signaling network
|
Internalization of ErbB1
|
Stabilization and expansion of the E-cadherin adherens junction
|
a6b1 and a6b4 Integrin signaling
|
Syndecan-3-mediated signaling eventserbb4_pathway:ErbB4 signaling events
|
ErbB2/ErbB3 signaling events
|
Validated targets of C-MYC transcriptional repression
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate Metabolism
|
Reactome
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
SHC1 events in ERBB2 signaling
|
PLCG1 events in ERBB2 signaling
|
PIP3 activates AKT signaling
|
GRB2 events in EGFR signaling
|
GAB1 signalosome
|
SHC1 events in EGFR signaling
|
EGFR downregulation
|
GRB2 events in ERBB2 signaling
|
PI3K events in ERBB2 signaling
|
EGFR Transactivation by Gastrin
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
Constitutive Signaling by EGFRvIII
|
RAF/MAP kinase cascadeR-HSA-1250196:SHC1 events in ERBB2 signaling
|
Sema4D induced cell migration and growth-cone collapse
|
RAF/MAP kinase cascade
|
WikiPathways
|
ErbB Signaling Pathway
|
Regulation of Actin Cytoskeleton
|
EGF/EGFR Signaling Pathway
|
MAPK Signaling Pathway
|
Focal Adhesion
|
Aryl Hydrocarbon Receptor Pathway
|
Extracellular vesicle-mediated signaling in recipient cells
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
Bladder Cancer
|
Hair Follicle Development: Induction (Part 1 of 3)
|
Signaling by ERBB4
|
Signaling by ERBB2
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
PIP3 activates AKT signaling
|
Nanoparticle-mediated activation of receptor signaling
|
Aryl Hydrocarbon Receptor
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Gastric cancer network 2
|
AGE/RAGE pathway
|
Signaling Pathways in Glioblastoma
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
Integrated Breast Cancer Pathway
|
Signaling by EGFR
|
L1CAM interactionsWP710:DNA Damage Response (only ATM dependent)
|
Leptin signaling pathway
|
Semaphorin interactions
|
References |
REF 1 | J Med Chem. 1999 May 20;42(10):1803-15.Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding siteof the epidermal growth factor receptor. |
---|
REF 2 | Nat Chem Biol. 2007 Apr;3(4):229-38. Epub 2007 Mar 4.Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. |